The goal of the program is to address root causes and improve metabolic health to the point where long-term reliance on medication is minimized
A total of six patients (11%) discontinued liraglutide due to adverse events, three of which were due to gastrointestinal disorders
Accumulating clinical evidence demonstrates that GLP-1 receptor agonists can improve markers of fatty liver disease, though the strength of evidence varies by outcome measure and specific medication
Pharmacotherapy: semaglutide treatment GLP-1 Receptor Agonists (GLP-1 RAs) are a group of medications used to treat type 2 diabetes and obesity by mimicking the incretin hormone GLP-1, thereby promoting blood glucose reduction and weight loss, along with providing added advantages such as lowering cardiovascular and renal risk
However, combining treatments may increase the chances of experiencing side effects
The survey included 1,955 participants: 495 current GLP-1 users, 468 former users, 492 potential users, and 500 non-users
